# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...
OpenAI and startup Color Health have developed an AI assistant, named 'copilot', to support physicians in creating pers...
- Reuters
"We are very pleased that mRNA-1283 has now met its primary vaccine efficacy endpoint in Phase 3, and showed higher efficac...
Oppenheimer analyst Hartaj Singh maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $163 to ...